IGM Biosciences pivots to autoimmunity, ends aplitabart work, names new CEO Mary Beth Harler

IGM Biosciences, Inc.

Strategic pivot to focus exclusively on T cell engagers for autoimmune diseases; aplitabart and other oncology programs minimized.
Mary Beth Harler, M.D. appointed CEO and director effective Sept 30, 2024; Fred Schwarzer resigns as CEO and director.
Bruce Keyt, Ph.D. steps down as CSO; Chris Takimoto, M.D., Ph.D. resigns as CMO effective Oct 1, 2024.
Cash runway extended into 2027; reduction in force expected; activities substantially complete by Q1 2025.
Imvotamab (CD20xCD3) ongoing in RA, SLE, myositis; IGM-2644 (CD38xCD3) expected to enter clinic for gMG by end of 2024.

item 2.05 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mary Beth Harler, M.D.

Chief Executive Officer and Director

IGM Biosciences, Inc.

Effective: 2024-09-30
Filed: October 3, 2024, 7:59 PM ET

Mary Beth Harler, M.D. has been appointed as the Company’s Chief Executive Officer, effective as of the Effective Date, and as a member of the Board (initial term ending at the annual stockholder meeting in 2025), effective as of October 1, 2024.

Departed

Fred Schwarzer

Chief Executive Officer, President and Director

IGM Biosciences, Inc.

Effective: 2024-09-30
Successor: Mary Beth Harler, M.D.
Filed: October 3, 2024, 7:59 PM ET

In connection with the Strategic Pivot, Fred Schwarzer resigned as Chief Executive Officer, President and a member of the board of directors (the “Board”) of the Company, effective as of September 30, 2024 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mary Beth Harler, M.D. was appointed as Chief Executive Officer and Director at IGM Biosciences, Inc..

Action: appointed
Role: Chief Executive Officer and Director

Exact text from the filing

Mary Beth Harler, M.D. has been appointed as the Company’s Chief Executive Officer, effective as of the Effective Date, and as a member of the Board (initial term ending at the annual stockholder meeting in 2025), effective as of October 1, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Fred Schwarzer resigned as Chief Executive Officer, President and Director at IGM Biosciences, Inc..

Action: resigned
Role: Chief Executive Officer, President and Director

Exact text from the filing

In connection with the Strategic Pivot, Fred Schwarzer resigned as Chief Executive Officer, President and a member of the board of directors (the “Board”) of the Company, effective as of September 30, 2024 (the “Effective Date”).

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-24-232252

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.